Artemisia annua is an herbal drug with profound antimalarial activity, which can be ascribed to the sesquiterpene lactone artemisinin. Artemisinin also shows efficacy against other parasitic protozoan species, such as Trypanosoma and Leishmania, however trypanocidal and leishmanicidal effects of A. annua extracts have not been reported so far. In the current study, we evaluated the in vitro growth inhibitory activity of a number of organic and aqueous A. annua extracts, including tinctures, infusions and decoctions against three parasitic protozoa, T. brucei rhodesiense, T. cruzi and L. donovani. Artemisinin content of these extracts was determined by HPLC/DAD/MS. Artemisinin was also evaluated for its antiparasitic activity for comparison. Among the tested extracts, the acetone-and the n-hexane-solubles of A. annua were the most potent against T. b. rhodesiense with IC 50 values of 0.30 and 0.455 μg/mL, respectively, whereas the other extracts were ten-to fifty-fold less potent. Neither of the extracts nor artemisinin had trypanocidal activity against T. cruzi (IC 50 > 30 μg/mL). Only the organic extracts of A. annua arrested the growth of L. donovani with modest IC 50 values (5.1 to 9.0 μg/mL) comparable to that of artemisinin (IC 50 8.8 μg/mL). This study highlights significant variations in the artemisinin content of A. annua extracts and underlines the potential of A. annua extracts and artemisinin in the treatment of trypanosomal and leishmanial infections.
Artemisia annua L. (Asteraceae) is an annual herb that has been used against fever in traditional Chinese medicine for over 2,000 years [1a] . The plant is nowadays listed in the Pharmacopoeia of the Republic of China for the treatment of fever and malaria. The recommended daily dose is specified as 4.5 to 9 g of dried herb prepared as a tea (infusion) with boiling water [1b] . After the discovery of artemisinin (1) as the antimalarial principle of the plant, all clinical studies have focused on this compound. Currently artemisinin-based combination therapy (ACT) is the most effective treatment of drug-resistant malaria and recommended by the WHO. A. annua is the sole source of artemisinin, which occurs in the plant in very low concentrations, resulting in high costs of therapy. Thus, there is an increasing interest in the use of A. annua teas in malaria endemic areas where large scale pharmaceutical production is not possible. Accordingly, the consumption of A. annua tea or decoctions by patients in clinical studies has been shown to reduce parasitaemia significantly [1c] .
Trypanosomiasis and leishmaniasis are insect-borne parasitic diseases that represent a significant and neglected public health problem worldwide. Trypanosoma brucei rhodesiense is the causative agent of African trypanosomiasis (sleeping sickness) in South and East Africa, infecting 50,000 people every year, primarily in the poorest rural populations of sub-Saharan Africa where the tsetse fly vector is common [1d] . The incidence of the disease may approach 500,000 cases per year. The American trypanosomiasis, also known as Chagas' disease caused by T. cruzi is a major endemic disease in South and Central America. It is estimated that 18 million people are infected with the disease and 50,000 individuals die of it annually [2] . Leishmaniasis is a tropical and subtropical disease affecting nearly 88 countries, with an estimated global prevalence of 12 million cases annually. It is caused by protozoal parasites of the genus Leishmania and occurs in three different clinical forms (cutaneous, muco-cutaneous and visceral), where visceral leishmaniasis (Kala azar), due to NPC Natural Product Communications 2008 Vol. 3 No. 12 1963 -1966 L. donovani and L. infantum, is the most severe form. Leishmaniasis presents as an opportunistic infection in association with immunodepression, in particular AIDS [3a] . Both trypanosomiasis and visceral leishmaniasis are invariably fatal if untreated. There is no prophylactic chemotherapy and little or no prospect of a vaccine. Moreover, current treatments of these diseases are far from being ideal because of the high costs, long treatment courses, high clinical failure and serious toxic, even fatal side effects. Thus, it is obvious that new drugs and therapy regimes are needed for the treatment of these diseases.
Besides its profound antimalarial effect, artemisinin has been shown to possess growth inhibitory effects against pathogenic Trypanosoma and Leishmania species [3b,3c] . However, the effects of different A. annua extracts have not been studied. In a previous study on a selected high-yield Brazilian cultivar of A. annua, we determined the artemisinin content of a number of solvent extracts, such as aqueous EtOH (tinctures AA-T40, AA-T60), infusions (AA-I1, AA-I2, AA-I3) and decoctions (AA-D1, AA-D2) by HPLC/DAD/MS and compared these with the artemisinin concentration in the n-hexane extract (AA-Hexane) [3d]. In the continuation of our studies on this A. annua cultivar, we have now prepared additional solvent extracts, namely toluene (AA-Toluene), dichloromethane (AA-DCM), acetone (AA-Acetone) and 100% ethanol (AA-EtOH). Their artemisinin content was determined by HPLC/DAD/MS, as previously reported [3d,3e] . All available extracts, as well as artemisinin were tested for in vitro activity against T. brucei rhodesiense, T. cruzi and L. donovani. Table 1 displays the quantitative analysis results on artemisinin content of all twelve extracts investigated. Percentages are given on the dried extracts obtained by evaporation of the organic solvent or freeze-dried aqueous solutions, and do not reflect the content of artemisinin in the dried herbal drug, which is about 0.52%. Very different artemisinin percentages were detected in the investigated extracts, with AA-DCM being the richest with 3.68% artemisinin. This extract was followed by EtOH, n-hexane and acetone extracts (2.64%, 2.28% and 1.82, respectively), whereas the toluene extract was the poorest (0.57%). The tinctures prepared with 40% v/v (AA-T40) and 60% v/v (AA-T60) EtOH had also lower artemisinin yields (0.75% and 1.08%), similar to those of A. annua infusions or decoctions, which contained roughly 0.7-0.8% artemisinin. 
Preparation of organic extracts:
Small pieces of dried aerial parts of A. annua (10 g) were exhaustively extracted at room temperature by maceration with 100 mL of organic solvent (toluene, n-hexane, acetone, dichloromethane or EtOH) for 72 h, separately. The filtrates were subsequently evaporated to dryness under reduced pressure to obtain the crude organic extract.
Preparation of the tinctures:
Small pieces of dried aerial parts of A. annua (10 g) were extracted at room temperature by maceration with 100 g of ethanol [either 40 or 60% v/v (samples T40 and T60)]. The solutions were concentrated under vacuum and freeze-dried prior to the analysis.
Preparation of the decoctions:
Sample D1: A 9 g sample of dried aerial parts of A. annua was extracted with 1 L of boiling water, kept boiling for 5 min, then left to cool and filtered through a filter paper. Sample D2: A 9 g sample of dried aerial parts of A. annua was extracted with 1 L of boiling water, kept boiling for 5 min and immediately filtered through a filter paper. For analytical purposes, both D1 and D2 (filtrates) were freeze-dried and directly analysed.
Preparation of the infusions:
Sample I1: A 9 g sample of dried A. annua was extracted with 1 L of boiling water, then left to cool and filtered through a filter paper. Sample I2: A 9 g sample of dried aerial parts of A. annua was extracted with 1 L of boiling water, covered, then left to cool and filtered through a filter paper. Sample I3: A 9 g sample of dried aerial parts of A. annua was extracted with 1 L of boiling water, then left to cool for 15 min and filtered through a filter paper. For analytical purposes, all infusions (filtrates) were freeze-dried and directly analysed.
HPLC-DAD and HPLC-MS systems:
The HPLC analyses were performed using a HP 1100 Liquid Chromatograph (Agilent Technologies, Palo Alto, CA, USA) equipped with a HP 1040 Diode Array Detector (DAD), an automatic injector, an auto sampler, a column oven and managed by a HP 9000 workstation (Agilent Technologies, Palo Alto, CA, USA). Separations were performed on a reversed phase column (Purospher ® Star RP-18, namely Hibar ® ). The HPLC system was interfaced with a HP 1100 MSD API-electrospray (Agilent Technologies, Palo Alto, CA, USA). The interface geometry, with an orthogonal position of the nebulizer with respect to the capillary inlet, allowed the use of analytical conditions similar to those of HPLC-DAD analysis. Mass spectrometry operating conditions were optimized in order to achieve maximum sensitivity values: gas temperature 350°C at a flow rate of 10 L/min, nebulizer pressure 30 p.s.i., quadrupole temperature 30°C, and capillary voltage 3500 V. Full scan spectra from m/z 100 to 800 in the positive ion mode were obtained (scan time 1 s). A prepacked column RT (250 x 4.6 mm) with particle size 5 µm (Merck, Darmstadt, Germany) was employed. The eluents were A: water adjusted to pH 3.2 with formic acid; B: acetonitrile; C: methanol. The system was operated with the oven temperature at 26 o C. Before HPLC analysis, each sample was filtered through a cartridge-type sample filtration unit with a polytetrafluoroethylene (PTFE) membrane (d=13 mm, porosity 0.45 µm, (Lida Manufacturing Corp.) and immediately injected. Chromatograms were recorded between 200 and 450 nm. DAD spectra were stored for all peaks exceeding a threshold of 0.1 mAu.
Calibration curves:
A calibration curve, obtained from a methanolic solution of artemisinin (1 mg/mL), was used to quantify artemisinin in the extracts and tinctures, while a methanolic solution of artemisinin (0.5 mg/mL) was employed to determine the artemisinin content of infusions and decoctions.
Sample analysis:
Samples of 5 mg of the different extracts were accurately weighed and suspended in methanol (1.0 mL). The suspensions were sonicated for 10 min and filtered through a cartridge-type sample filtration unit before HPLC analysis. The tinctures were injected as prepared.
In vitro assay for Trypanosoma brucei rhodesiense:
Minimum Essential Medium (50 μL) supplemented according to [4a] 
In vitro assay for Leishmania donovani:
Amastigotes of Leishmania donovani strain MHOM/ET/67/L82 were grown in axenic culture at 37°C in SM medium [4b] at pH 5.4 supplemented with 10% heat-inactivated fetal bovine serum under an atmosphere of 5% C0 2 in air. Culture medium (100 μL) with 1 x 10 5 amastigotes from axenic culture with or without a serial drug dilution were seeded in 96-well microtiter plates. Seven 3-fold dilutions were used covering a range from 30 to 0.041 μg/mL. After 72 h of incubation, 10 μL of Alamar Blue™ was added to each well. The plates were incubated for another 2 h and read with a Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, Sunnyvale, CA, USA) using an excitation wavelength of 536 nm and an emission wavelength of 588 nm. Data were analyzed using the software Softmax Pro (Molecular Devices Cooperation, Sunnyvale, CA, USA). Decrease of fluorescence (= inhibition) was expressed as percentage of the fluorescence of control cultures and plotted against the drug concentrations. From the sigmoidal inhibition curves the IC 50 values were calculated.
